Overcoming Challenges in Non-Muscle Invasive Bladder Cancer and Metastatic Castration-Resistant Prostate Cancer

Overcoming Challenges in Non-Muscle Invasive Bladder Cancer and Metastatic Castration-Resistant Prostate Cancer

Non-muscle invasive bladder cancer (NMIBC) and metastatic castration-resistant prostate cancer (mCRPC) present unique diagnostic and therapeutic challenges. In this article, we will explore these challenges and discuss strategies for overcoming them.

NMIBC is a type of bladder cancer that has not invaded the muscle layer of the bladder. It is typically diagnosed through cystoscopy and biopsy. The management of NMIBC depends on the risk of progression to muscle-invasive disease. High-risk features, such as HG T1 disease with additional risk factors like concomitant CIS, lymphovascular invasion, prostatic urethral involvement, and variant histology, warrant initial radical cystectomy as recommended by guidelines. However, not all patients may wish to undergo surgery or receive alternative intravesical therapies.

For patients treated with intravesical BCG (Bacillus Calmette-Guérin) who develop muscle-invasive disease, outcomes are worse compared to those with de novo disease when managed with radical cystectomy. Early cystectomy remains the primary guideline-recommended therapy for BCG-unresponsive NMIBC.

Moving on to mCRPC, up to 30% of patients have deleterious alterations in genes associated with homologous recombination repair (HRR). Recent studies have focused on the use of niraparib, abiraterone acetate (AAP), and prednisone as first-line therapy for mCRPC with and without HRR gene alterations.

The MAGNITUDE Phase 3 study evaluated the efficacy and safety of niraparib with AAP and prednisone in this patient population. The study found that patients randomized to the niraparib arm had lower rates of ECOG performance status 0 and higher rates of visceral metastases. Additionally, BRCA1 mutations were more common in the niraparib arm.

Despite the added toxicity, no added efficacy was observed in patients with HRR-negative mCRPC. The Independent Data Monitoring Committee (IDMC) recommended stopping enrollment in these cases. The most common adverse events leading to dose reduction in the AAP plus niraparib group were anemia and thrombocytopenia. Dose reductions and discontinuation of niraparib or placebo were more frequent in the niraparib group.

In the MAGNITUDE study, the primary endpoint of radiographic progression-free survival (rPFS) was tested first in the BRCA1/2 subgroup. If statistical significance was reached, the remainder of the HRR-positive patients would be analyzed. For the HRR-negative cohort, a pre-specified futility analysis was planned after enrolling 200 patients and approximately 125 composite events had occurred. Stratification was done based on prior treatments for metastatic hormone-sensitive prostate cancer (mHSPC), AR pathway inhibitors, and AAP. In the HRR-positive cohort, stratification was also done based on BRCA1/2 alterations.

In light of these challenges, here are three actionable pieces of advice for clinicians managing NMIBC and mCRPC:

1. Individualize treatment decisions: It is important to consider the patient's preferences and risk factors when deciding on the optimal management strategy for NMIBC. Discuss the potential benefits and risks of radical cystectomy and alternative intravesical therapies to help patients make informed decisions.

2. Genetic testing in mCRPC: Given the prevalence of HRR gene alterations in mCRPC, consider incorporating genetic testing into the diagnostic workup. Identifying these alterations can help guide treatment decisions and identify patients who may benefit from therapies like niraparib.

3. Regular monitoring and dose adjustments: Close monitoring of patients receiving niraparib with AAP is crucial to manage adverse events effectively. Regular blood count monitoring can help identify and manage anemia and thrombocytopenia. Prompt dose adjustments and discontinuations when necessary can help optimize patient outcomes.

In conclusion, both NMIBC and mCRPC present unique challenges in terms of diagnosis and treatment. By understanding the risk factors and tailoring treatment approaches accordingly, clinicians can overcome these challenges and provide optimal care to their patients. Incorporating genetic testing and closely monitoring patients receiving targeted therapies can further improve outcomes.